For a translational perspective, we next evaluated the ability of TERT-based ACT to limit the in vivo progression of HLA-A2+ hCD19+ cells isolated from two different cryopreserved B-ALL patient's BM aspirates (referred as B-ALL#1 and B-ALL#2 respectively). This evidence concerns the gene TERT and acute lymphoblastic leukemia.